Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Share-based Compensation (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Share-based Compensation data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2.31% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $12.4 million, up 14.08%, while the annual FY2025 figure was $12.4 million, 14.08% up from the prior year.
  • Share-based Compensation reached $2.9 million in Q4 2025 per ACRS's latest filing, up from $2.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.8 million in Q1 2023 and bottomed at $1.3 million in Q4 2023.
  • Average Share-based Compensation over 5 years is $3.6 million, with a median of $3.3 million recorded in 2025.
  • The widest YoY moves for Share-based Compensation: up 190.11% in 2023, down 73.7% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.9 million in 2021, then grew by 24.98% to $4.8 million in 2022, then plummeted by 73.7% to $1.3 million in 2023, then skyrocketed by 125.91% to $2.9 million in 2024, then grew by 2.31% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.9 million in Q4 2025, $2.9 million in Q3 2025, and $3.1 million in Q2 2025.